173 related articles for article (PubMed ID: 11356103)
1. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Sarau HM; Griswold DE; Potts W; Foley JJ; Schmidt DB; Webb EF; Martin LD; Brawner ME; Elshourbagy NA; Medhurst AD; Giardina GA; Hay DW
J Pharmacol Exp Ther; 1997 Jun; 281(3):1303-11. PubMed ID: 9190866
[TBL] [Abstract][Full Text] [Related]
7. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.
Malherbe P; Bissantz C; Marcuz A; Kratzeisen C; Zenner MT; Wettstein JG; Ratni H; Riemer C; Spooren W
Mol Pharmacol; 2008 Jun; 73(6):1736-50. PubMed ID: 18308898
[TBL] [Abstract][Full Text] [Related]
8. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
[TBL] [Abstract][Full Text] [Related]
9. Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.
Giardina GA; Artico M; Cavagnera S; Cerri A; Consolandi E; Gagliardi S; Graziani D; Grugni M; Hay DW; Luttmann MA; Mena R; Raveglia LF; Rigolio R; Sarau HM; Schmidt DB; Zanoni G; Farina C
Farmaco; 1999 Jun; 54(6):364-74. PubMed ID: 10443017
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of cloned human NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf-21 insect cell system.
Aharony D; Little J; Powell S; Hopkins B; Bundell KR; McPheat WL; Gordon RD; Hassall G; Hockney R; Griffin R
Mol Pharmacol; 1993 Aug; 44(2):356-63. PubMed ID: 8394992
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
[TBL] [Abstract][Full Text] [Related]
12. Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.
Sarau HM; Mooney JL; Schmidt DB; Foley JJ; Buckley PT; Giardina GA; Wang DY; Lee JA; Hay DW
Mol Pharmacol; 2000 Sep; 58(3):552-9. PubMed ID: 10953048
[TBL] [Abstract][Full Text] [Related]
13. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
Meini S; Bellucci F; Catalani C; Cucchi P; Patacchini R; Rotondaro L; Altamura M; Giuliani S; Giolitti A; Maggi CA
Eur J Pharmacol; 2004 Mar; 488(1-3):61-9. PubMed ID: 15044036
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.
Meini S; Catalani C; Bellucci F; Cucchi P; Giuliani S; Zappitelli S; Rotondaro L; Pasqui F; Guidi A; Altamura M; Giolitti A; Maggi CA
Eur J Pharmacol; 2005 Jun; 516(2):104-11. PubMed ID: 15925360
[TBL] [Abstract][Full Text] [Related]
15. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
Bissantz C; Bohnert C; Hoffmann T; Marcuz A; Schnider P; Malherbe P
J Med Chem; 2012 Jun; 55(11):5061-76. PubMed ID: 22574973
[TBL] [Abstract][Full Text] [Related]
16. Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
Choppin A; Groke G; Bringas A; Stepan G; Dillon MP
Pharmacology; 2002 May; 65(2):96-102. PubMed ID: 11937780
[TBL] [Abstract][Full Text] [Related]
17. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
18. Isolation and pharmacological characterization of a hamster urinary bladder neurokinin A receptor cDNA.
Aharony D; Little J; Thomas C; Powell S; Berry D; Graham A
Mol Pharmacol; 1994 Jan; 45(1):9-19. PubMed ID: 8302285
[TBL] [Abstract][Full Text] [Related]
19. High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template.
Harrison T; Korsgaard MP; Swain CJ; Cascieri MA; Sadowski S; Seabrook GR
Bioorg Med Chem Lett; 1998 Jun; 8(11):1343-8. PubMed ID: 9871763
[TBL] [Abstract][Full Text] [Related]
20. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
